Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of EA Pharma.

    Client Virtual Booth

    EA PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    EA Pharma
    France Flag
    Country
    Country
    France
    Address
    Address
    Vallauris, Provence-Alpes-Cote d'Azur
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ea-pharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ea-pharma/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    “MOVICOL® HD” Launched - A New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan

    Details:

    MOVICOL® HD is a high dose formulation of existing “MOVICOL® LD”, the first polyethylene glycol indicated for treatment of chronic constipation1) in Japan. MOVICOL® HD contains the same active ingredients in double the quantity of MOVICOL® LD per sachet.


    Lead Product(s): Macrogol

    Therapeutic Area: Gastroenterology Product Name: Movicol HD

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Mochida Pharmaceutical

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 20, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    All-case Surveillance Condition for Approval of “Actonel® 17.5 mg tablets” for Treatment of Paget’s Disease of Bone Cleared in Japan

    Details:

    Actonel (risedronate sodium hydrate) tablet act as inhibits osteoclasts, which is indicated for the treatment of Paget’s disease and treatment and prevention of postmenopausal osteoporosis.


    Lead Product(s): Risedronate Sodium

    Therapeutic Area: Rare Diseases and Disorders Product Name: Actonel

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Eisai

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 19, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search